Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma-Reference-Cited by-同舟云学术

Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma

Published:2020-01-16 Issue:2 Volume:61 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Australas J Dermatol

Author:

García‐de‐la‐Fuente Mª Reyes¹²^ORCID,Santacana Maria²³^ORCID,Verdaguer Joan²⁴^ORCID,Vilardell Felip³^ORCID,Garí Eloi²⁵^ORCID,Casanova Josep Manel¹²⁶^ORCID

Affiliation:

1. Department of Dermatology University Hospital Arnau de Vilanova Lleida Spain

2. Lleida Institute for Biomedical Research Dr. Pifarré Foundation (IRBLleida) Lleida Spain

3. Department of Pathology University Hospital Arnau de Vilanova Lleida Spain

4. Immunology Unit Department of Experimental Medicine University of Lleida Spain

5. Department of Basic Medical Sciences University of Lleida Spain

6. Department of Medicine University of Lleida Lleida Spain

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.13229

Reference16 articles.

1. Update of the European guidelines for basal cell carcinoma management

2. Basal Cell Carcinoma: An Evidence-Based Treatment Update

3. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma

4. Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%

5. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: Results of a randomized phase IIa trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lesiones premalignas de piel y mucosas y carcinoma escamoso in situ;FMC - Formación Médica Continuada en Atención Primaria;2023-03

2. Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study;Skin Health and Disease;2022-08-10

3. Natural Killer Cell Recognition and Control of Epithelial Cancers;The Cancer Journal;2022-07

4. A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma;Future Oncology;2021-08